Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Editas And Celgene Amend Existing Collaboration To Develop And Commercialize Autologous And Allogeneic T Cell Medicines For Treatment Of Cancer And Autoimmune Diseases; Editas To Receive $70M And Is Eligible For Royalty And Milestone Payments

Author: Benzinga Newsdesk | November 12, 2019 08:21am

Posted In: CELG EDIT

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

07/16/2024 Vestis Corporation (VSTS)

07/22/2024 Biogen Inc. (BIIB)

07/23/2024 Fastly, Inc. (FSLY)